经尿道前列腺内麻醉(TUIA)使用Schelin导管在iTIND术前应用
该研究首次评估Schelin导管(SC)行经尿道前列腺内麻醉(TUIA)在iTIND置入前的应用,23例患者中11例(48%)接受SC TUIA,其余接受标准麻醉方案。装置植入和移除时疼痛无差异,但TUIA组在24小时(1.0 vs 3.0)和48小时(1.0 vs 2.5)随访时中位VAS评分显著更低。SC TUIA在iTIND过程中提供有效疼痛控制,支持其在门诊环境中使用。
要点
- 23例患者中11例(48%)接受SC TUIA,其余接受标准麻醉。
- 装置植入和移除时两组疼痛无差异。
- TUIA组24小时和48小时中位VAS评分显著低于标准麻醉组。
核心结论
- SC TUIA在iTIND过程中提供有效疼痛控制,支持其在门诊环境中使用。
研究设计与样本
- 首次评估Schelin导管(SC)行经尿道前列腺内麻醉(TUIA)在iTIND置入前的应用,23例患者入组,11例(48%)接受SC TUIA,其余接受标准麻醉方案。
主要发现
- 装置植入和移除时两组疼痛无差异。
- TUIA组24小时中位VAS评分为1.0,标准麻醉组为3.0,TUIA组显著更低。
- TUIA组48小时中位VAS评分为1.0,标准麻醉组为2.5,TUIA组显著更低。
临床怎么用
- 原文结论支持SC TUIA在iTIND过程中用于门诊环境下的疼痛控制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Endorsing the principles of minimal invasiveness in benign-prostatic hyperplasia (BPH) surgery, we conducted the first evaluation of transurethral intraprostatic anesthesia (TUIA) using Schelin catheter® (SC) prior to iTIND positioning. SUBJECTS/METHODS: Of 23 patients enrolled, 11 (48%) received TUIA via SC whereas the remaining underwent standard anesthesia protocol. Pain was assessed using visual analogue scale (VAS). RESULTS: No differences between cohorts were observed for pain during the device implantation and removal. Conversely, significantly lower median VAS scores were reported at 24- (1.0 vs. 3.0) and 48- (1.0 vs. 2.5) hour follow-up favoring TUIA. CONCLUSIONS: SC TUIA offers effective pain control during iTIND procedures, supporting its use in outpatient settings.
引用
- Secco S, Olivero A, Longoni M, et al. Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure. Prostate Cancer Prostatic Dis. 2024. PMID: 39256552. doi:10.1038/s41391-024-00892-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。